NEW: Premarket Now Starts at 4AM!

We’re excited to announce the extension of premarket and aftermarket hours! Our members now have access to quotes daily from 4:00 AM to 8:00 PM ET — offering greater flexibility and deeper insights into market trends beyond regular trading hours.

Upgrade to FINVIZ*Elite to access premarket quotes »

SNY

Sanofi ADR

May 08 • 04:00PM ET

52.13

Dollar change -0.14
Percentage change -0.27	%

Healthcare • Drug Manufacturers - General • France • NASD

Peers: NVS PFE MRK GSK BMY LLY AZN JNJ ABBV AMGN

| Held by: PVAL GCOW FVD PPH PID AVDE APIE QQQJ PINK PLDR

Scroll to Statements

Index	-	P/E	21.77	EPS (ttm)	2.39	Insider Own	0.02%	Shs Outstand	2.61B	Perf Week	-3.64%
Market Cap	126.99B	Forward P/E	10.36	EPS next Y	5.03	Insider Trans	0.00%	Shs Float	2.44B	Perf Month	4.55%
Income	6.02B	PEG	1.65	EPS next Q	0.95	Inst Own	10.80%	Short Float	0.16%	Perf Quarter	-1.40%
Sales	44.44B	P/S	2.86	EPS this Y	23.25%	Inst Trans	-1.09%	Short Ratio	1.38	Perf Half Y	-1.55%
Book/sh	32.01	P/B	1.63	EPS next Y	9.89%	ROA	4.29%	Short Interest	3.95M	Perf Year	5.68%
Cash/sh	3.21	P/C	16.23	EPS next 5Y	13.20%	ROE	7.34%	52W Range	45.80 - 60.12	Perf YTD	8.09%
Dividend Est.	2.34 (4.49%)	P/FCF	15.97	EPS past 5Y	13.05%	ROI	6.39%	52W High	-13.28%	Beta	0.54
Dividend TTM	2.04 (3.91%)	Quick Ratio	0.73	Sales past 5Y	2.13%	Gross Margin	63.49%	52W Low	13.82%	ATR (14)	1.35
Dividend Ex-Date	May 09, 2025	Current Ratio	1.08	EPS Y/Y TTM	2.96%	Oper. Margin	23.14%	RSI (14)	44.93	Volatility	1.73% 2.22%
Employees	84587	Debt/Eq	0.23	Sales Y/Y TTM	-4.57%	Profit Margin	13.54%	Recom	1.58	Target Price	66.56
Option/Short	Yes / Yes	LT Debt/Eq	0.17	EPS Q/Q	-	Payout	66.96%	Rel Volume	0.66	Prev Close	52.27
Sales Surprise	3.35%	EPS Surprise	3.11%	Sales Q/Q	-	Earnings	Apr 24 BMO	Avg Volume	2.86M	Price	52.13
SMA20	-0.69%	SMA50	-4.59%	SMA200	-1.83%	Trades		Volume	1,884,577	Change	-0.27%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-15-25	Initiated	Exane BNP Paribas	Outperform	$65
Mar-21-25	Initiated	Goldman	Neutral	$65
Jan-30-25	Upgrade	Deutsche Bank	Sell → Hold
Jul-26-24	Reiterated	Argus	Buy	$55 → $60
Jan-23-24	Initiated	Morgan Stanley	Equal-Weight	$55
Jan-16-24	Resumed	UBS	Buy
Dec-05-23	Downgrade	JP Morgan	Overweight → Neutral
Oct-30-23	Downgrade	Stifel	Buy → Hold
Sep-06-23	Upgrade	Berenberg	Hold → Buy
Jul-14-23	Initiated	HSBC Securities	Buy
Apr-28-23	Downgrade	Deutsche Bank	Hold → Sell
Mar-27-23	Upgrade	Barclays	Equal Weight → Overweight
Dec-13-22	Resumed	Morgan Stanley	Overweight
Aug-12-22	Upgrade	Deutsche Bank	Sell → Hold
Aug-09-22	Downgrade	UBS	Buy → Neutral
May-23-22	Initiated	SVB Leerink	Outperform
Sep-27-21	Upgrade	SVB Leerink	Mkt Perform → Outperform
Jan-15-21	Initiated	Deutsche Bank	Sell
Sep-29-20	Initiated	Berenberg	Hold
Mar-17-20	Upgrade	Barclays	Underweight → Equal Weight

Show Previous Ratings

May-08-25 01:31PM	COVID Vaccine Maker Novavax Stock Soars 16% - Here's Why (Benzinga)
01:25PM	Sanofi exec tells biotechs not to scrimp on clinical trial design (Clinical Trials Arena)
May-07-25 01:11PM	Cytokinetics Q1 Earnings Beat, Aficamten Target Action Date Extended (Zacks)
01:10PM	Denali Q1 Loss Wider Than Expected, Hunter Syndrome Drug in Focus (Zacks)
May-05-25 07:12AM	Novavax to Report First-Quarter Earnings: Is a Beat in Store? (Zacks)
03:04AM	Loading…
03:04AM	European Firms Fare Better Than Feared Through Early Trade Pain (Bloomberg)
May-02-25 01:23PM	BioMarin's First-Quarter Earnings & Sales Beat Estimates (Zacks)
12:00PM	Sanofi: Information concerning the total number of voting rights and shares - March 2025 (GlobeNewswire)
May-01-25 01:30PM	Moderna: Regulatory Hurdles And Market Challenges Prompt Downgrade To Sell (Seeking Alpha)
08:15AM	Sanofi (SNY, Financials) Completes Opella Deal, Creates Consumer Health Leader (GuruFocus.com)
Apr-30-25 12:46PM	Press Release: Annual General Meeting of April 30, 2025 (GlobeNewswire)
11:45AM	GSK Q1 Earnings Beat, Sales Lag, Stock Gains on Tariff Reassurance (Zacks)
11:30AM	The Davenport Balanced Fund Q1 2025 Commentary (Seeking Alpha)
10:30AM	The Davenport Value & Income Fund Q1 2025 Commentary (Seeking Alpha)
07:00AM	Press Release: Sanofi and CD&R close Opella transaction, create global consumer healthcare leader (GlobeNewswire)
03:12AM	Loading…
03:12AM	Swedish Orphan Biovitrum AB (BIOVF) Q1 2025 Earnings Call Highlights: Strong Haematology Growth ... (GuruFocus.com)
Apr-29-25 01:22PM	Regeneron Stock Falls on Q1 Earnings and Sales Miss, Eylea Sales Down (Zacks)
09:12AM	AZN Q1 Earnings Beat, Stock Down on Soft Sales Performance of Key Drugs (Zacks)
08:27AM	Regeneron's first-quarter results miss on lower Eylea demand (Reuters)
07:00AM	Press Release: When every second counts: Sanofi, McLaren Racing and United Autosports join forces to raise meningitis awareness at Le Mans 24 Hours race (GlobeNewswire)
Apr-28-25 08:16AM	Private Equity Firms Target Defense Assets Once Seen as Toxic (Bloomberg)
Apr-27-25 11:40PM	Why AbbVie's Stock Is A Strong Buy After Q1 2025 Results (Seeking Alpha)
Apr-25-25 06:34AM	Halozyme sues Merck; FDA blames cuts for Vanda delay (BioPharma Dive)
05:13AM	Analyst Report: Sanofi (Morningstar Research)
01:47AM	Swiss Agree to Tariff Negotiations With Trump Administration (Bloomberg)
12:01AM	Sanofi and Sobi extend their partnership with the World Federation of Hemophilia Humanitarian Aid Program (PR Newswire)
Apr-24-25 04:13PM	Pharma Giant Roche Tops First-Quarter Views; Sanofi's Sales Come In Mixed (Investor's Business Daily)
02:03PM	Sanofi (SNY) Q1 2025 Earnings Call Transcript (Seeking Alpha)
12:40PM	Sanofi axes development of oral TNF inhibitor as monotherapy following Phase II fail (Clinical Trials Arena)
10:03AM	French Drugmaker Sanofi Clocks 20% Q1 Profit Growth, Forecasts Strong Rebound In Annual Profit (Benzinga)
07:59AM	Loading…
07:59AM	Sanofi Q1 Earnings Top Estimates, Dupixent Drives Sales Growth (Zacks)
07:00AM	Sanofi stays on course amid tariff turmoil (BioPharma Dive)
04:48AM	Sanofi Sales, Profit Beat Expectations on Higher Demand for Skin, Asthma Drug (The Wall Street Journal)
01:30AM	Press Release: Sanofi: strong Q1 performance and 2025 guidance confirmed (GlobeNewswire)
Apr-23-25 02:50PM	Why vaccine makers aren't worried about Trump administration cuts (Yahoo Finance)
12:37PM	Biotech Stock Roundup: BMY Down on Study Data, Updates From REGN & More (Zacks)
09:25AM	The Zacks Analyst Blog Highlights Gilead Sciences, Bristol Myers, Merck, AbbVie and Sanofi (Zacks)
02:44AM	European pharma companies push for higher drug prices in EU amid U.S. tariff threats (Reuters)
Apr-22-25 09:06AM	Will These 5 Large Drug Maker Stocks Surpass Q1 Earnings Forecast? (Zacks)
07:40AM	Celldex Therapeutics: Strong Pipeline But Uncertainties Remain (Seeking Alpha)
Apr-21-25 04:05PM	Deep Track Capital Files Definitive Proxy Statement and Sends Letter to Fellow Shareholders (Business Wire)
09:22AM	Sanofi & Regeneron's Dupixent Receives FDA Nod for Urticaria (Zacks)
08:21AM	Should You Buy, Sell or Hold AstraZeneca Stock Before Q1 Earnings? (Zacks)
05:10AM	Sanofi and Regenerons dupilumab approved by FDA for urticaria (Pharmaceutical Technology)
Apr-19-25 11:20AM	Regeneron, Sanofi announce FDA approval of Dupixent for CSU (TipRanks)
Apr-18-25 11:15AM	Press Release: Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticaria (GlobeNewswire)
11:15AM	Dupixent (dupilumab) Approved in the U.S. as the First New Targeted Therapy in Over a Decade for Chronic Spontaneous Urticaria (CSU) (GlobeNewswire)
09:13AM	Sanofi, Regeneron win FDA nod for Dupixent in chronic hives (BioPharma Dive)
Apr-17-25 05:07PM	Nurix Therapeutics: IRAK4 GS-6971 Isn't Only Protein Degrader With Big Potential (Seeking Alpha)
09:15AM	Pharma Stock Roundup: J&J's Q1 Results, PFE's Obesity Setback (Zacks)
07:19AM	Sanofi licenses immune disease drugs from startup Earendil (BioPharma Dive)
05:54AM	Glycomine secures $115m funding for Phase IIb trial of rare disease drug (Pharmaceutical Business Review)
Apr-16-25 11:47AM	Sanofi Advances Mid-to-Late-Stage Pipeline in Respiratory Indications (Zacks)
06:28AM	Dodge & Cox Global Stock Fund Q1 2025 Shareholder Letter (Seeking Alpha)
05:55AM	Dodge & Cox Stock Fund Q1 2025 Shareholder Letter (Seeking Alpha)
Apr-15-25 08:00AM	Chrissy Teigen - author, entrepreneur, mom to young son with type 1 diabetes - joins Sanofi's Screen For Type 1 movement (PR Newswire)
05:39AM	Tariff wars to hit popular US-made drugs in China, regulator data shows (Reuters)
01:00AM	Press Release: Sanofi's respiratory pipeline advances with new data in asthma and plans for new clinical studies in COPD (GlobeNewswire)
Apr-11-25 09:07AM	Why You Shouldn't Bet Against Sanofi (SNY) Stock (Zacks)
08:39AM	Novavax: Regulatory Uncertainty Creates Risk And Opportunity For Beaten-Down Vaccine Developer (Seeking Alpha)
Apr-10-25 10:39AM	Harbor Dividend Growth Leaders ETF Q4 2024 Commentary (Seeking Alpha)
Apr-09-25 12:03PM	AAN 2025: Sanofis tolebrutinib likely to be first BTK inhibitor for the treatment of MS (Clinical Trials Arena)
12:03PM	Top Stock Movers Now: Delta, Apple, Eli Lilly, and More (Investopedia)
10:28AM	Pharma Stocks Sink as Trump Says 'Major' Tariffs Coming to Industry (Investopedia)
09:51AM	Novo Nordisk, AbbVie Stocks Slide After Trump Vows Pharma Tariffs (The Wall Street Journal)
08:17AM	Novo Nordisk, AbbVie, Other Stocks Tumble After Trump Threatens Pharma Tariffs (The Wall Street Journal)
06:17AM	Pharma Stocks Drop After Trump Threatens Tariffs on Medicines (The Wall Street Journal)
05:40AM	Trump Says Pharmaceutical Tariffs Coming Very Shortly (Bloomberg)
Apr-08-25 01:11PM	Press Release: Tolebrutinib phase 3 data published in NEJM demonstrate benefit on disability progression in multiple sclerosis (GlobeNewswire)
Apr-07-25 09:08AM	Syndax Pharmaceuticals: Down But Not Out (Seeking Alpha)
Apr-06-25 04:46AM	All the Stocks Warren Buffett Bought in the Last 2 Recessions: Are They Smart Picks Now? (Motley Fool)
02:36AM	Regeneron: Market Overlooks A Resilient Franchise And Robust Free Cash Flow (Seeking Alpha)
Apr-05-25 03:00PM	Tariffs Stoke Fears That Hung Debt Will Return (Bloomberg)
Apr-04-25 09:46AM	Pharma Stock Roundup: FDA Nod to SNY, AZN & NVS, JNJ Talc Suits Failure (Zacks)
04:51AM	FDA awards ODD status to Sanofis rilzabrutinib for two rare conditions (Pharmaceutical Technology)
Apr-03-25 02:08PM	Sanofi: Information concerning the total number of voting rights and shares - February 2025 (GlobeNewswire)
11:27AM	SNY's Rilzabrutinib Gets FDA's Orphan Drug Tag for Two Rare Diseases (Zacks)
09:08AM	NRIX Stock Up as SNY In-Licenses Rights to Autoimmune Diseases Program (Zacks)
01:00AM	Press Release: Rilzabrutinib granted orphan drug designation in the US for two rare diseases with no approved medicines (GlobeNewswire)
Apr-02-25 09:20AM	Sanofi: Qfitlia Approval A Bright Spot As Landscape Darkens For European Pharma (Seeking Alpha)
08:20AM	Leqembis EU review drags on; Sanofi gets a new development head (BioPharma Dive)
Apr-01-25 12:42PM	Is Sanofi (SNY)the Best Gene-Editing Stock to Buy? (Insider Monkey)
09:44AM	SNY Gets FDA Nod for First Ever Hemophilia Drug in the United States (Zacks)
05:27AM	Japan's MHLW authorises Regeneron and Sanofi's Dupixent for COPD (Pharmaceutical Business Review)
Mar-31-25 10:55AM	Sanofis Qfitlia approved by FDA as first haemophilia therapy for all patients (Pharmaceutical Technology)
08:28AM	FDA Approves Sanofi's Hemophilia Drug (Benzinga)
06:20AM	Is First Trust Value Line Dividend ETF (FVD) a Strong ETF Right Now? (Zacks)
Mar-28-25 04:07PM	Press Release: Qfitlia approved as the first therapy in the US to treat hemophilia A or B with or without inhibitors (GlobeNewswire)
02:27PM	US FDA approves Sanofi's bleeding disorder therapy (Reuters)
01:39PM	FDA approves first-of-its-kind RNA drug for hemophilia (BioPharma Dive)
09:44AM	AbbVie Vs. Sanofi: Which Is The Better Investment Right Now (Seeking Alpha)
09:29AM	Corvus Pharmaceuticals: Now At Cruising Altitude (Seeking Alpha)
03:01AM	Innate Pharma SA (IPHA) (FY 2024) Earnings Call Highlights: Strategic Advances and Financial ... (GuruFocus.com)
02:00AM	Press Release: Dupixent approved as the first-ever biologic medicine in Japan for patients with COPD (GlobeNewswire)
02:00AM	Dupixent (dupilumab) Approved as the First-ever Biologic Medicine in Japan for Patients with Chronic Obstructive Pulmonary Disease (COPD) (GlobeNewswire)
01:00AM	ClearBridge International Value ADR Portfolios Q4 2024 Commentary (Seeking Alpha)
Mar-27-25 05:37PM	Analyst Report: Sanofi (Morningstar Research)
11:34AM	Merck Gets EC Nod for 21-Valent Pneumococcal Jab Capvaxive (Zacks)
11:30AM	U.S. to end funding for child vaccines in developing countries, NY Times reports (TipRanks)
10:20AM	ClearBridge International Value Fund Q4 2024 Commentary (SeekingAlpha)

Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

SNY

Sanofi ADR

Upgrade your FINVIZ experience